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1.1 Anatomy and histopathology 
The prostate gland, a triangular shaped organ weighing around 20g to 30g is located 
anterior to the rectum, inferior to the urinary bladder and surrounds the bladder neck and 
proximal urethra. It can be categorised into five lobes, the anterior lobe, median lobe, two 
lateral lobes and the posterior lobe. In a healthy young male, the physiologically normal 
dimensions are approximately 4cm in width, 3cm in height and 2cm in length (1).  
The prostate gland is divided into three main zones each with different embryological 
origins. These are known as the peripheral, central and transition zones. In a young adult these 
areas account for 70%, 25% and 5% of the volume of the prostate gland respectively. The vast 
majority of prostate carcinomas arise in the peripheral zone and 60-70% are found in this area 
(2).  Regarding histology, over 90% of prostate carcinomas are adenocarcinomas. The 
remaining 5% are heterogeneous which includes cells of stromal, epithelial, or ectopic origin 
(2). 
 
1.2 Epidemiology and risk factors 
In Western populations, prostate cancer has become the most common male cancer 
and the third most common cause of cancer death in Europe. In Croatia, prostate cancer is the 
third most common male cancer after lung and colorectal cancer (3).  
The geographical distribution of prostate cancer incidence differs extensively among 
different populations and ethnicities worldwide. The most commonly affected regions include 
Australia, New Zealand, North America and Northern and Western Europe. Incidence rates 
are also relatively high in less developed regions such as the Caribbean, South Africa and 
Southern America. On the contrary, the lowest rates have been reported in Central and 
Eastern European countries and Asia (4).  
Prostate specific antigen (PSA) is a screening measure that is more effective at 
detecting incidence than it is at detecting mortality. Access to screening varies in different 
regions and as a result, leads to a disparity in incidence rates in the world. On the other hand, 
mortality remains stable regardless of location (4).   
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The increased incidence of prostate cancer can be attributed to various reasons. Firstly, 
there is a longer average life expectancy compared to the past. More people live longer than 
70 years and are therefore more likely to reach an older age in which  prostate cancer 
incidence is higher. Secondly, an increased diagnostic rate especially in the use of PSA for 
screening asymptomatic, otherwise healthy individuals has lead to a significant increase in the 
age-adjusted incidence rates of the disease. Consequently, prostate cancers that are small and 
would have previously gone undetected are found and recorded (5). The discrepancy among 
regions in the world may reflect access to preventive and diagnostic tools. Further to this, the 
differences may be attributed to other aspects such as genetic, environmental factors, diet and 
lifestyle (4).  
There are three well-established risk factors for prostate cancer: old age, a positive 
family history and ethnicity. Firstly, the average age for a diagnosis of prostate cancer is 67 
years and the median age for death is 81 years (6). Out of all cancers, the incidence of prostate 
cancer increases the most when it comes to age. In fact, it is almost universal at postmortem in 
men aged over 80 years (5). Moreover, patients who have a first-degree relative with a 
diagnosis of prostate cancer have double the risk of developing prostate cancer compared to 
those who do not have a diagnosed first-degree relative (6). When it comes to race, the 
mortality rate among African-American men is almost twice that of Caucasian men. 
Furthermore, there is a higher mortality rate in less developed countries as opposed to 
developed countries (4).  
Further risk factors include the total dietary fat intake; animal fat and red meat are 
associated with an increased risk. Consumption of fish, conversely, has been shown to be 
protective. Additionally, lycopene, selenium, vitamin E and omega-3 fatty acids correlate with 
a lower risk, whereas vitamin D and calcium increase the risk (2).    
 
1.3 Screening 
Prostate cancer screening is a set of diagnostic tests which is perfomed at regular 
intervals aimed primarily at apparently healthy males from the general population. This 
allows for the detection of cancer in an early pre-clinical phase. As a result, screening has 
proved beneficial as early management can be initiated which can reduce prostate cancer 
mortality as well as maintain quality of life (7).   
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Current EU guidelines recommend that screening should begin early for men who are 
at increased risk of prostate cancer. Men who fall under this category are those who are over 
50 years, over 45 years of age with a family history of prostate cancer, African-Americans, 
men with a PSA level of > 1 ng/mL at 40 years of age and men with a PSA level of > 2 
ng/mL at 60 years of age (7). 
Prostate cancer is usually suspected on the basis of PSA measurement and digital 
rectal exam (DRE). In previous years, DRE was the principle method of prostate cancer 
screening. However, there is a variability of detection among different examiners and the 
majority of cancers detected with this method are already at an advanced stage. Furthermore, 
the positive predictive value is only 11%–26% and so when used alone DRE is insufficient for 
screening (8). This method has now been surpassed by PSA measurement which came into 
practice in 1980. Although there is no evidence to suggest that testing reduces the risk of 
death from prostate cancer it does however allow for patients to be categorised into those who 
will develop clinically significant disease from those who will not (5). For a total PSA value 
to be considered normal it should be below 4 ng/ml. A PSA between 4 and 10 ng/ml has a 
positive predictive value of around 20-30%. When the value exceeds 10 ng/ml the positive 
predictive value increases to 71.4% (2). An elevated PSA level will warrant further 
evaluation. 
There are some limitations to using PSA measurements and these should be taken into 
consideration. The main issue is that PSA is prostate specific but not prostate cancer specific. 
False positive results can be obtained because other benign prostate conditions can also 
elevate PSA levels. Examples include BPH, prostatitis, urethral instrumentation and perineal 
insults (2). These should be kept in mind when a patient has an elevated PSA level. 
Free PSA can be measured in order to distinguish prostate cancer from benign disease 
in patients with total PSA values between 4 and 10 ng/ml. Patients with prostate cancer 
typically produce more complexed PSA in which PSA is bound to proteins. In contrast, 
benign prostate cells produce more free PSA. The ratio of free to total PSA can facilitate the 
decision of whether a biopsy is appropriate for the patient (9).  
Patients who have an elevated PSA level, abnormal DRE or a combination of the two 
should be considered for a transrectal ultrasound (TRUS) guided biopsy. Twelve core biopsies 
are obtained from the prostate gland at the base, mid-gland and apex. The definitive diganosis 
can subsequently be confirmed by histopathological analysis (10). 
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1.4 Symptoms and presentation of prostate cancer 
Many asymptomatic prostate cancers have been identified as a result of screening. 
When prostate cancer does become symptomatic, it may cause a patient to experience any of 
the following symptoms: impotence, urinary retention, urinary frequency, urinary hesitancy, 
nocturia and hematuria. A number of these symptoms do however overlap with benign 
prostate conditions which are more likely to be the cause. For example, patients with benign 
prostate hypertrophy often complain of urinary frequency, urgency, and hesitancy (11).  
Symptoms of prostate cancer vary depending on how far the disease has progressed 
and whether the spread is lymphatic, hematogenous or contiguous (12). Prosate cancer can 
spread locally to the seminal vesicles, ureters, bladder base and external urethral sphincter 
which typically leads to the symptoms of prostatism. Lymphatic involvement commonly 
includes the iliac chain in the early stages and can progess to the para-aortic lymph nodes in 
more advanced disease. Hematogenous involvement is responsible for metastasis to the bones, 
liver, lung and adrenal glands (8).  
Advanced prostate cancer symptoms include weight loss, anemia, ostealgia possibly 
with pathologic fracture, neurologic deficits due to spinal cord compression, lower extremity 
pain and edema due to obstruction of venous and lymphatic vessels by nodal metastasis. Some 
of the aforementioned symptoms can be explained by the strong predilection of prostate 
cancer to metastasise to the skeletal system (12). As a matter of fact, more than 80% of those 
who die of prostate cancer have evidence of this (8). Uremic symptoms can also result if there 
is obstruction of the ureter due to local prostate growth or retroperitoneal adenopathy 
secondary to nodal metastasis (12).  
 
1.5 Gleason score 
The Gleason score, obtained following biopsy is a grading system for prostate 
adenocarcinoma based on five histological growth patterns or grades. Many prostate 
adenocarcinomas demonstrate two or more Gleason patterns. The primary and secondary 
Gleason patterns are added together to produce the Gleason score (Table 1). They are 
categorised according to the degree of glandular differentiation (Table 2). The first grade is 
the most differentiated histology type and therefore represents the most favourable prognosis. 
On the other hand, the fifth grade correlates to the least differentiated type and thus indicates a 
poor prognosis (13). 
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Table 1. Gleason score grading system. This table was taken from Chen N et al.  
 
Grade       Gleason score   
 
1               Gleason 6 (or less) 
2               Gleason 3+4=7 
3               Gleason 4+3=7 
4               Gleason 8 
5               Gleason 9-10                
 
 
Table 2. Gleason pattern. This table was taken from Mazhar D et al. 
 
Grade   Gleason score   
 
1           Well differentiated carcinoma with uniform gland pattern 
2           Well differentiated with glands varying in size and shape 
3           Moderately differentiated carcinoma 
4           Poorly differentiated carcinoma with fused glands  
5        Very poorly differentiated carcinoma with no or minimal gland formation
 
  
1.6 Staging 
Following biopsy, prostate cancer can be staged according to the TNM classification. 
This acronymic classification system represents the size of the tumor (T), the lymph node 
involvement (N) and the presence of metastases (M) (Figure 1). In addition to evaluating the 
risk of prostate cancer spreading beyond the prostate gland, the TNM score can establish 
whether local therapy, such as surgery or radiation is appropriate (14).  
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Figure 1. TNM staging score for prostate cancer. This picture was taken from 
http://reference.medscape.com/slideshow/prostate-cancer-6004678#18. 
Prostate cancer is categorised from stage I (the least advanced) to stage IV (the most 
advanced) using information obtained from the TNM stage, Gleason score and PSA (Figure 
2). The treatment and prognosis can then be determined by the stage allocated to that 
particular patient (14).  
                         
Figure 2. Staging of prostate cancer. This picture was taken from 
http://reference.medscape.com/slideshow/prostate-cancer-6004678#18. 
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Diagnostic PSA ≥ 20 ng/ml or highest biopsy Gleason score ≥ 8 or 
clinical stage T2c/T3 
 
1.7 Risk stratification 
Current trends of prostate cancer management show overtreatment of low-grade 
disease and undertreatment of high-grade disease. With the intention of reducing this pattern, 
over 100 risk formulae, lookup tables, nomograms, and other tools have been developed to 
target this and stratify risk accordingly (2).  
Risk stratification is done in order to assess the risk of recurrences following local 
treatment of prostate cancer which subsequently allows the patient to make a more informed 
decision about their treatment plan with regards to disease-free survival.  At present, localised 
prostate cancer is risk stratified according to PSA level at diagnosis, Gleason histological 
grade and T score from the TNM classification (15). This model is based on the D’amico 
classification which came about in 1998 and allocates each patient into one of three risk 
groups: low, intermediate and high (16) (Table 3).  
Table 3. D’amico risk stratification for clinically localised prostate cancer. This table was 
taken from http://www.cancernetwork.com/cancer-management/prostate-cancer/page/0/1. 
 
Risk                          Criteria    
 
Low risk       
 
Intermediate risk    
 
High risk               
 
Another method of risk stratification is the Cancer of the Prostate Risk Assessment 
(CAPRA) score. It was developed in 2005 by Cooperberg et al and is used to stratify prostate 
cancer risk preoperatively. Risk is indicated on a scale of 1-10. Points are allocated according 
to: PSA at the time of diagnosis, Gleason score, clinical stage, the percentage of positive 
biopsy cores and age. The CAPRA score is now used to predict the risk of bone metastasis 
and prostate cancer-specific mortality. Each increase in CAPRA score has been linked to an 
increased risk of prostate cancer specific morbidity or mortality (16).      
Diagnostic PSA <10.0 ng/ml and highest biopsy Gleason score ≤6 and                 
clinical stage T1c or T2a 
Diagnostic PSA ≥ 10 but < 20 ng/ml or highest biopsy Gleason score = 7 
or clinical stage T2b  
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The National Comprehensive Cancer Network (NCCN) has further improved risk 
stratification by classifying men into five risk groups as opposed to the original three. In these 
guidelines, the intermediate group has been split into low-intermediate and high-intermediate 
groups (16). Additionally, a very low-risk group has been included for patients who have a 
very low risk of dying from prostate cancer in the next 10 to 20 years. This allows patients to 
avoid aggressive treatment if they are more suitable for an active surveillance approach (15).  
In order to achieve more accurate risk stratification in the future, further information is 
being added to stratification methods such as MRI and genomic profiling (16).  
1.8 Treatment of local Prostate cancer 
1.8.1 Watchful waiting and active surveillance 
Watchful waiting and active surveillance are both types of expectant management. 
They involve an initial surveillance which is followed by treatment only in the case of 
symptomatic disease progression. These conservative management strategies are used with 
the intention of avoiding over treatment and in doing so preserve quality of life (7).  
The priniciple difference between the two is that treatment in watchful waiting is 
palliative and in active surveillance it is curative. Therefore, treatment in watchful waiting 
aims to control disease whereas active surveillance is reserved for patients who are more 
likely to be cured should treatment be started (17). Moreover, active surveillance involves 
more frequent investigations than watchful waiting including prostate biopsies and MRIs (7). 
Generally, patients who are allocated to watchful waiting are older, have comorbidities 
and have a low stage of disease. This method is suitable for patients who have a life 
expectancy of less than 10 years or have another more serious illness that is more life-
threatening than their prostate cancer. Moreover, patients with comorbitities are less likely to 
tolerate treatments such as radiotherapy or surgery (7). 
Active surveillance is suitable for patients with a low risk of cancer progression. This 
subset of patients include those with localised cancer, a life expectancy of more than 10 years 
and are more likely to tolerate treatment (7).  
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1.8.2 Radical prostatectomy 
Radical prostatectomy involves the removal of the entire prostate gland, adjacent 
bladder neck, seminal vesicles, vas deferens and the surrounding fascia in the anticipation that 
the prostate cancer can be completely eradicated (5). Radical prostatectomy is currently 
considered to be the first line of treatment when it comes to the removal of localised cancer. 
This is a surgery that is indicated for men who have a life expectancy exceeding 10 years and 
prostate cancer that is localised to the prostate gland i.e. stages T1-T2. As a sole treatment, it 
has cured the majority of patients with organ-confined disease or with well-differentiated 
tumors (18).  
Prostatectomy can also be combined with radiotherapy so as to gain a better control 
over the cancer. Postoperative radiotherapy may be suitable if the area surrounding the 
excision margins or pelvic lymph nodes are involved (5). Following prostatectomy serial PSA 
levels are taken in order to assess whether there is any progression of disease (19). PSA 
should be undetectable and if present suggests that there is residual disease. This is a further 
indication that postoperative radiotherapy would be beneficial (5). 
As with most surgeries, there are a number of side effects and complications to 
consider following radical prostatectomy. Side effects include short-term constipation, urinary 
incontinence, erectile dysfunction, infertility, possible blood loss due to the surgery, in rare 
cases there may be injury to the rectum and there is also a very low chance of post-operative 
mortality (19).  
In the interest of minimising erectile dysfunction, nerve-sparing techniques can be 
used during surgery to preserve the neurovascular bundle. However, this is not always 
recommended if prostate cancer is more advanced and cancerous cells may have invaded the 
surrounding neural structures (19).  
 
1.8.3 Prostate cancer radiotherapy 
External beam radiotherapy uses high energy X-rays as a source of ionising radiation 
from outside the body to target and destroy cancerous prostate cells and discontinue or slow 
their growth (20). Types of external beam radiotherapy include 3D conformal radiotherapy 
(3D-CRT) and intensity-modulated radiation therapy (IMRT). 
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Radiotherapy may be used as a curative or as a palliative treatment. Radiotherapy as a 
curative therapy is suitable for men who have localised prostate cancer and for those with 
locally advanced prostate cancer. Patients who have advanced or metastatic cancer may be 
offered radiotherapy as a palliative measure to help control symptoms such as ostealgia (20).  
There are various methods in which radiotherapy is applied. These include 
radiotherapy as a primary, neoadjuvant, adjuvant and salvage treatment (5). Further 
discussion of the latter two methods can be found in a subsequent section. 
Both 3D-CRT and IMRT allow for treatment planning so that a focused dose of 
radiation can be targeted at cancer cells. Side effects are reduced because a high dose can 
conform to the desired target volume whilst sparing the surrounding healthy tissues. 3D-CRT 
uses CT to create a 3D image reconstruction of the prostate gland. IMRT, on the other hand, 
allows for modulation of the radiation beam intensity and so higher doses of radiation can be 
applied compared to 3D-CRT. IMRT may be added to conformal therapy to further intensify 
the radiation of cancerous tissues (21).  
There are various side effects linked with radiotherapy of the prostate gland. These 
may be short or long-term side effects. Patient risk factors leading to a higher likelihood of 
side effects are in those who are older, have diabetes melitus, inflammatory bowel disorders, 
previous abdominal surgery or hemorrhoids (22).  
In the short-term, radiotherapy can cause radiation cystitis leading to symptoms such 
as dysuria, pollakiuria, urinary retention, hematuria and urinary incontinence (20,22). 
Moreover, radiotherapy can cause gastrointestinal problems including an increased urge to 
defecate, the discharge of rectal mucus and hematochezia (22). Further short-term side effects 
include: fatigue, anejaculation, skin irritation and hair loss around the site of radiation (20). 
Following the cessation of radiotherapy these acute side effects tend to resolve quickly (22).  
Genitourinary symptoms, gastrointestinal symptoms and erectile dysfunction, as 
mentioned previously, may also become long-term side effects. Erectile dysfunction may be 
successfully treated with phosphodiesterase-5 inhibitors (22). Further long-term side effects 
include ostealgia and osteoporosis as radiotherapy may damage osteocytes and the blood 
supply of the surrounding bones. Additionally, semen quality can be affected so patients may 
decide to collect and store their semen for future use and should consider appropriate 
contraception (20). Due to the damage caused by radiotherapy, there is a small chance of 
secondary malignancy formation which can occur after around 10-15 years (22). 
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1.8.4 Brachytherapy 
Patients may also receive brachytherapy alongside external beam radiotherapy. 
Brachytherapy is another sort of radiotherapy in which radioactive material is placed directly 
into the prostate gland. There are two different types of brachytherapy based on the rate of 
radiation. These are either low dose rate (LDR) or high dose rate (HDR) brachytherapy. In 
LDR brachytherapy radioactive ‘seeds’ are placed into the prostate gland permanently and 
emit radiation to the prostate and surrounding tissues in order to destroy cancer cells. The 
radioactive ‘seeds’ are placed via TRUS guidance and contain either iodine-125 or palladium-
103 (2). LDR is suitable for patients who have localised prostate cancer. HDR brachytherapy 
also involves the placement of radioactive material to target cancerous cells, however, unlike 
LDR, it is temporary and is used over a shorter time period. HDR brachytherapy is more 
suited to patients with locally advanced prostate cancer and is often used in conjunction with 
external beam radiotherapy or hormone therapy (23).  
 
1.8.5 Hormone therapy 
Prostate cancer is dependent on androgens for its maintenance and progression. 
Consequently, hormone therapy is effective because it reduces the amount of androgens in the 
body and thus decreases the growth of the tumor (24).  
Hormone therapy is known as androgen deprivation therapy (ADT). ADT directly 
antagonises androgen receptors at the level of the prostate gland or regulates the release of 
androgens from the hypothalamic-pituitary axis (GnRH agonists) (5). Flutamide and 
bicalutamide are examples of androgen receptor antagonists. These can be used alone or in 
combination with surgical castration to block the effect of androgens. GnRH agonists, on the 
other hand, include Leuprolide and Goserelin (24).  
There are numerous indications for ADT. It may be used as a primary treatment to 
palliate symptoms in patients who are unsuitable for definitive treatment with surgery or 
radiation or in those who have relapsed following primary treatment. ADT can also be used in 
the neoadjuvant setting prior to definitive radiotherapy to shrink the size of the tumor and 
allow for better symptom control in patients with locally advanced tumors. ADT used as an 
adjuvant therapy following definitive radiotherapy or surgery has been shown to provide an 
improvement in survival (5). 
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The androgen biosynthesis pathway elucidates the mechanism of GnRH agonists. The 
pathway begins at the level of the hypothalamus which secretes gonadotropin-releasing 
hormone (GnRH) in a pulsatile manner. This in turn stimulates the adenohypophysis to 
release the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) 
(25). LH is responsible for the production of testosterone via the Leydig cell receptors which 
are found in the testes. Approximately 90% of testosterone is synthesised in the testes and the 
remaining testosterone is synthesised by the adrenal glands from its precursor cholesterol. 
Testosterone is then converted into its active metabolites; dihydrotestosterone (DHT) and 
estradiol (24). The continuous stimulation of the GnRH receptors leads to their eventual 
desensitisation or downregulation which results in suppressed gonadotropin release and a 
consequent drop of testosterone levels to castrate levels (25).  
Upon initiation of treatment with GnRH agonists, there is an exacerbation of clinical 
symptoms due to the initial surge of testosterone levels (25). Patients should take anti-
androgens prior to and for the first 2-4 weeks of therapy with GnRH agonists to cover the 
initial flare. It takes approximately 4-8 weeks for GnRH analogues to reach testosterone 
castration levels within the desired target range (24).  
Castration can be achieved in a surgical or medical manner. The target of castration is 
to lower testosterone levels to less than 50 ng dl−1 and in practice levels of below 20 ng dl−1 
are usually attained (24). Surgical castration via bilateral surgical orchiectomy attains similar 
results to ADT because it directly removes the major source of androgen production (5). 
However, contemporary practice demonstrates that GnRH agonists are the preferred castration 
method and are the standard of long-term hormonal therapy (24). This can be attributed to 
their ease of administration and their reversibility. Moreover, patients are more likely to 
favour such medical therapy because of the emotional and psychological impact associated 
with surgical castration (25).         
 
1.9 Adjuvant and salvage radiotherapy after radical prostatectomy 
Adjuvant radiotherapy is used 1-6 months following radical prostatectomy in the 
absence of any signs of recurrence and involves applying radiotherapy to the prostate bed, the 
seminal vesicle bed and to the area of pelvic lymph nodes. Adjuvant radiotherapy has been 
shown to reduce the risk of biochemical recurrence and significantly improve the metastasis-
free survival (26).  
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Salvage radiotherapy, on the other hand, is initiated when there are signs of 
biochemical recurrence post-prostatectomy following a period of early surveillance of PSA to 
detect any disease progression (27).  
Adjuvant radiotherapy was favoured over salvage radiotherapy for use in high-risk 
patients to reduce the risk of biochemical recurrence and death whilst improving the clinical-
recurrence free survival. Patients with a high-risk profile may profit more from adjuvant 
therapy rather than surveillance followed by salvage therapy. Salvage radiotherapy however, 
has been shown to provide a comparable survival benefit to adjuvant radiotherapy and may be 
essential in the prevention of patient overtreatment (27).  
         
1.10 Treatment of metastatic prostate cancer 
Worldwide, prostate cancer represents the most commonly diagnosed cancer and is the 
sixth principle cause of cancer-related death (28). In the European Union (EU) alone, more 
than 70,000 men die of prostate cancer every year (29). 
Prostate cancer initially presents as castration-naïve before transitioning to the fatal 
castration-resistant phenotype. Androgen deprivation is the cornerstone of treatment at the 
initial castration-naïve stage and is achieved with androgen deprivation therapy (ADT), 
orchiectomy or a combination of the two (24). 
In newly diagnosed castration-naïve metastatic prostate cancer, the early administration of 
docetaxel chemotherapy or abiraterone acetate at the time of first-line long-term hormone 
therapy is associated with increased overall survival (OS). In clinical trials, the addition of 
docetaxel to ADT increased median survival by 10 months when compared to ADT alone. 
Therefore, men who are fit enough to receive chemotherapy should have docetaxel added to 
the standard of care (30). Abiraterone acetate, an inhibitor of the CYP17A1 enzyme involved 
in the intracellular production of androgens (31), also demonstrated an increase in OS when 
combined with ADT compared to ADT use alone. In clinical trials, a 37% increase in overall 
survival (OS) was reported in the combination group. Consequently, abiraterone acetate 
should likewise be considered for use alongside hormone therapy in this subset of patients 
(32).   
In the majority of patients, ADT keeps disease under control for only 12 to 18 months 
before advanced prostate cancer inevitably becomes castration resistant (33).  
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Castration-resistant prostate cancer is defined as disease progression biochemically or 
radiologically despite levels of testosterone below 50 ng per decilitre (1.7 nmol per litre). 
According to guidelines from the European Association of Urology, biochemical progression 
is defined as "three consecutive rises in PSA 1 week apart resulting in two 50% increases over 
the nadir, and a PSA of more than 2 ng/mL." Radiological progression, on the other hand, is 
"the appearance of new lesions: either two or more new bone lesions on bone scan or a soft 
tissue lesion using RECIST (Response Evaluation Criteria in Solid Tumors)." Symptomatic 
progression itself is not sufficient for a diagnosis of CRPC and must subsequently be followed 
up by further investigation (7).  
The castration-resistant state is invariably fatal and typically leads to death within 24 to 
48 months following its onset (34). The therapeutic armamentarium available today has 
allowed for extension of patient survival via the use of six indispensable treatments. Among 
these are: the taxanes- docetaxel and cabazitaxel; novel androgen receptor (AR) pathway 
inhibitors- abiraterone acetate and enzalutamide; and bone targeting alpha emitting 
radionuclide- Radium 223 chloride. The addition of these therapies to our arsenal in the fight 
against prostate cancer has ameliorated outcomes and has led to increased overall survival and 
health-related quality of life alongside other parameters (35).  
In castration-resistant prostate cancer, the use of enzalutamide and abiraterone acetate 
has been shown to increase overall survival before and after the use of chemotherapy agents 
(40,41).  
Enzalutamide was initially approved for use in mCRPC post-docetaxel therapy in 
2012. However in 2014, its usage was extended to chemotherapy-naïve patients (36).  
Enzalutamide works by competitively binding to the ligand binding domain of the androgen 
receptor. Pre-chemo use of enzalutamide in comparison to placebo resulted in an 81% 
reduction of radiographic progression and a 29% decrease in the risk of death. Moreover, 
enzalutamide improved quality of life and delayed the need for cytotoxic chemotherapy (28). 
Similarly, abiraterone acetate was shown to be of significant benefit in chemotherapy-
naïve mCRPC. Radiological progression free survival (rPFS) and OS were increased when 
compared with placebo. There was a significant improvement in rPFS in the abiraterone group 
of 16.5 months compared with 8.3 months in the prednisone alone group. Moreover, patients 
who received abiraterone with prednisone had a 25% decreased risk of death (34).  
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The use of AR-targeted therapies before chemotherapy is fundamental in CRPC 
treatment. To date, enzalutamide and abiraterone acetate are the only oral treatments approved 
in the treatment of mCRPC. On the other hand, docetaxel and cabazitaxel are intravenous 
chemotherapies which require administration at the hospital and are associated with many 
adverse events. As such, prophylactic measures and a high degree of caution should be 
maintained during chemotherapy. As standard practice, oral therapies are prescribed first in 
most mCRPC and when signs of progression are detected chemotherapy can be started if 
appropriate (37). 
Chemotherapy used in mCRPC includes docetaxel and cabazitaxel. Docetaxel, which 
was approved for use in 2004, is associated with increased survival and is the first line 
chemotherapy agent in mCRPC (38). In the case of docetaxel-resistant mCRPC, cabazitaxel is 
the second line chemotherapy treatment. Cabazitaxel is a tubulin-binding taxane drug which is 
just as potent as docetaxel and is the first drug to improve survival in this setting (39).  
In the post chemotherapy space, various medications have been used including 
abiraterone acetate and enzalutamide. Two large phase III trials, COU-AA-301 and AFFIRM, 
confirmed significant benefit with post-chemotherapy use of abiraterone acetate and 
enzalutamide respectively. Both trials were eventually unblinded considering the success of 
the treatments and patients were allowed to crossover and receive treatment instead of placebo 
if they met the criteria (40,41). 
The COU-AA-301 trial demonstrated improved survival when abiraterone acetate was 
used post-chemotherapy in mCRPC patients. Abiraterone plus prednisone reduced the risk of 
death by 35.4 % and increased overall survival by 3.9 months in comparison to placebo plus 
prednisone. Besides increasing overall survival, abiraterone acetate was superior to placebo 
with respect to PSA response rate, time to PSA progression, median rPFS and objective 
response rate according to the RECIST criteria in patients with measurable disease at baseline 
(40). Adverse events associated with abiraterone acetate are linked to the increased production 
of mineralocorticoids following CYP17 blockade. This includes fluid retention, edema, 
hypokalemia and hypertension (36). Other second-line hormonal agents do not increase OS 
and have less favorable safety profiles when compared to abiraterone acetate. On the whole, 
abiraterone acetate was associated with a good compliance and its toxicity was mainly related 
to mineralocorticoid overproduction which could easily be reversed via the use of prednisone 
(40).                        
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The AFFIRM trial showed a prolongation of survival with post-chemotherapy 
enzalutamide when compared to placebo. Enzalutamide increased OS by a median of 4.8 
months and reduced the risk of death by 37%. Moreover, enzalutamide was significantly 
superior to placebo in all of the defined secondary end points: PSA-level response rate, soft-
tissue response rate, FACT-P quality-of-life-response, the time to PSA progression, rPFS and 
the time to first SRE. Further to this, adverse events of grade 3 or above were less frequent in 
the enzalutamide group and the median time to adverse events with enzalutamide was 12.6 
months compared to 4.2 months with placebo. However, a higher incidence of all grades of 
fatigue, diarrhea, hot flushes, musculoskeletal pain, and headache was reported in the 
enzalutamide group (41). Enzalutamide should be administered with care because it can 
provoke seizures in a small percentage of patients particularly those who are predisposed to 
having a seizure (28). This includes patients with a history of seizures, underlying brain injury, 
stroke, brain metastases, alcoholism or the use of other medications that lower seizure 
threshold. Therefore, enzalutamide is not suitable for use in this particular subset of patients. 
Overall, enzalutamide is an indispensable therapy for use post-chemotherapy because it 
prolongs survival and is well tolerated due to its favourable side effect profile (41).  
Prostate cancer has a predilection to metastasise to bone tissue and more than 90% of 
patients with mCRPC are found to have such metastases. This has several severe 
consequences including disability, decreased quality of life, increased treatment costs and 
even death. In contrast to other types of cancer, the majority of prostate cancer deaths are due 
to bone disease and its associated complications (42).   
Approximately 20-40% of patients with mCRPC and bone metastases do not receive 
chemotherapy because they are too frail (ECOG >2), have coexisting conditions or do not 
wish to have chemotherapy. The use of Ra-223 addresses this important group of patients (42). 
Radium-223, an alpha emitter, has been shown to increase survival and reduce skeletal related 
events whilst having minimal adverse effects on surrounding healthy tissue. Ra-223 was 
approved for use in 2013 for mCRPC with symptomatic bone metastases but no known 
visceral involvement (43).  
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2. OBJECTIVES 
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To retrospectively compare the efficacy of abiraterone acetate and enzalutamide in the 
treatment of patients with mCRPC in the post-docetaxel setting outside of randomised clinical 
trials and in real clinical practice. This was measured in terms of biochemical, radiological 
and clinical progression free survival (i.e. bPFS, rPFS and cPFS, respectively) and OS in 58 
consecutive patients in a single institution. We also evaluated the toxicity of both agents. 
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3. MATERIALS AND METHODS 
 21 
 
In this retrospective cohort study data was collected from patients’ charts in the 
Department of Oncology and Radiotherapy in Split. A total of 58 consecutive mCRPC 
patients (n=58) treated with abiraterone acetate (1000 mg/day, 1h before or 2h after meal) 
plus prednisone (2x5 mg) (n=27) and enzalutamide (160 mg per day) (n=31) from October 
2015 until May 2018 in the post-docetaxel setting were included in this study.   
 
All patients had castrate levels of serum testosterone (< 50 ng/dl or 1.7 nmol/l). 
Patients were treated until there was progression of disease or unacceptable toxicity.  In order 
to stop treatment, two out of three criteria for progression (i.e. biochemical, radiological or 
clinical) should be fulfilled. For each cycle patients were evaluated for toxicity, biochemical 
progression with PSA and clinical progression.  Patients were evaluated every three cycles for 
radiological progression with bone scintigraphy, abdominal/ pelvic CT or ultrasound and 
chest X-ray using RECIST criteria (Response Evaluation Criteria in Solid Tumors) and 
PCWG-2 criteria (Prostate Cancer Working Group) for bone metastases progression.   
 
Statistical analysis was performed using descriptive statistics by means of Microsoft 
Excel and SPSS 16.0 software packages. For survival analysis, the Kaplan-Meier method was 
used. To prove the probability of null hypothesis accuracy, a t-test with a confidence interval 
of 95% was used and a p value ≤ 0.05 was considered statistically significant. 
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4. RESULTS  
 23 
 
Table 4. Patients’ characteristics with abiraterone acetate (AA+P) or enzalutamide (ENZ) 
treatment. 
                              Characteristics                 Treatment (n=58) 
Age, months (median)   AA+P   (n=27)   ENZ (n=31) 
71 72 
Gleason score, n, (%) 3+3 2 (7) 9 (29) 
3+4 8 (30) 5 (16) 
4+3 5 (18) 6 (19) 
8-10 12 (44) 11(35) 
Unknown 1 (3) 1 (3) 
Initial stage, n (%) Localized 7 (26) 12 (38) 
Metastatic 20 (74) 20 (62) 
Duration of response to first ADT, months (median) 17 26 
Site of metastases, n (%) Bones 11 (41) 18 (58) 
Lymph nodes (LN) 4 (15) 2 (6) 
Bones + LN 6 (22) 9 (29) 
Visceral +/- other 3 (11) 4 (13) 
Previous lines of hormonal 
treatment, n (%) 
1 10 (37) 12 (38) 
2 13 (48) 15 (48) 
3 4 (15) 5 (16) 
4 0 (0) 1  (3) 
Duration of response to docetaxel, months (median) 9 8 
Type of progression on    
docetaxel,% 
Biochemically (B) 6 (22) 8 (26) 
Radiologically (R) 0 (0) 1 (3) 
B+R+Clinically (C) 4 (15) 9 (29) 
B+R 12 (44) 9 (29) 
B+C 4 (15) 3 (9) 
R+C 0 (0) 4 (13) 
ECOG status 0 11 (41) 9 (29) 
1 13 (48) 16 (52) 
2 3 (11) 7 (23) 
Symptoms (bone pain 
according to VAS-scale), n 
(%) 
Asymptomatic 9 (33) 7 (23) 
Mildly symptomatic 16 (59) 16 (52) 
Symptomatic 2 (7) 9 (29) 
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The median follow up time in this study was 12.8 months and the data cut-off point was May 
15
th
 2018. The median duration of therapy was 6 months for patients treated with AA+P, and 
7 months for patients treated with ENZ.   
OS was not reached (NR) for AA+P patients and was 24 months for ENZ patients,  P=0.6878 
(Figure 1). 
 
 
 
 
 
 
 
 
Figure 1. – Kaplan-Meier curves for OS. 
 
bPFS was 8 months for AA+P patients and 5.5 months for ENZ patients,  P=0.6153      
(Figure 2).   
 
 
 
 
 
 
 
    
Figure 2. – Kaplan-Meier curves for bPFS. 
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rPFS was 11.5 months for AA+P patients and was 8 months for ENZ patients, P=0.2692 
(Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. – Kaplan-Meier curves for rPFS.  
 
 
cPFS was 15 months for AA+P patients  and was 13 months for ENZ patients, P= 0.5592 
(Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. – Kaplan-Meier curves for cPFS.  
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Table 5. Toxicity recorded in patients’ charts. 
Adverse event AA+P 
(n=27) 
  ENZ 
(n=31) 
Vertigo,n (%) Gr I 1 (4) 2 (6) 
Back pain,n (%) Gr I 1 (4) 0 (0) 
Gr II 1 (4) 0 (0) 
Fatigue,n (%) Gr I 7 (26) 0 (0) 
Gr II 2 (7) 4 (13) 
Bone pain,n (%) Gr I 8 (30) 9 (29) 
Gr II 3 (11) 5 (16) 
Anemia,n (%) Gr I 3 (11) 3 (10) 
Gr II 2 (7) 3 (10) 
Thrombocytopenia,n 
(%) 
Gr I 3 (11) 0 (0) 
Gr II 0 (0) 1 (3) 
Fever,n (%) Gr I 1 (4) 1 (3) 
Gr II 1 (4) 0 (0) 
Decreased appetite, n 
(%)  
Gr I 1 (4) 2 (6) 
Gr II 0 (0) 1 (3) 
Hypokalemia, n(%) Gr I 2 (7) 0 (0) 
Lower leg edema, n (%) Gr I 1 (4) 0 (0) 
Gr II 1 (4) 0 (0) 
Elevated liver enzymes Gr I 1 (4) 0 (0) 
Gr II 0 (0) 2 (6) 
Nausea Gr I 2 (7) 0 (0) 
Vomiting Gr I 2 (7) 0 (0) 
Diabetes mellitus Gr I 1 (4) 0 (0) 
Hyperbilirubinemia Gr I 1 (4) 2 (6) 
Cognitive disorder Gr I 0 (0) 2 (6)  
Hypertension Gr II 1 (4) 0 (0) 
Diarrhea Gr II 0 (0) 1 (3) 
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5. DISCUSSION 
 28 
 
The objective of this small retrospective analysis was to obtain information about the 
efficacy and toxicity of two relatively new and expensive drugs abiraterone acetate plus 
prednisone and enzalutamide (AA + P and ENZ) in the treatment of our 58 mCRPC patients 
in the post-docetaxel setting. This was done with unselected patients in real clinical practice 
and provides data about these agents beyond randomized clinical trials. 
Despite the numerical difference in mOS, bPFS, rPFS, cPFS, in this relatively small 
number of patients, there was no statistically significant difference found between the two 
groups. From these results the conclusion is that both drugs were equally effective in our 
mCRPC patients in the post- docetaxel setting.  
If we compare the results of mOS in our groups of mCRPC patients with the results of 
the most important randomized trials for AA + P (i.e. COU-AA 301) and ENZ (i.e. AFFIRM), 
it shows that the results of our patients' treatment with these agents were even better. Namely, 
in the COU-AA 301 study, mOS was 14.8 months (40) while in our mCRPC patients treated 
with AA+P mOS was not reached. In the AFFIRM trial, mOS was 18.4 months (41) whereas 
in our mCRPC patients treated with ENZ mOS was 24 months.  
In other observed parameters such as bPFS (8.0 months for AA + P and 5.5 months for 
ENZ ) or rPFS (11.5 months for AA + P and 8.0 months for ENZ) we achieved comparable 
results to the  COU-AA 301 trial (10.2 or 5.6 months, respectively) (40) and the AFFIRM 
study (8.3 and 8.3 months, respectively) (41). 
Regarding the observed toxicity in our population of patients, the incidence of certain 
side effects (among other typical side effects for each drug) did not differ significantly from 
those observed in the randomized trials mentioned above (40,41). Moreover, most of the 
recorded side-effects were of grade I or II. This is incredibly important in this patient 
population who have a limited survival. This is not only because it allows for extension of 
overall survival but also because quality of life can be maintained with such therapies due to 
favourable toxicity profiles. 
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The main limitation of the present study was the small sample size of patients which 
limits the utility of such data on a universal basis. However, despite the small sample size, 
results of a comparable nature to previously conducted larger trials were obtained. With 
respect to this, it is clear to see that both ENZ and AA provide significant benefits for patients 
in terms of mOS, bPFS, rPFS, cPFS in Split. In order to address this particular limitation on a 
larger scale, future research on a greater subset of patients in Split would be very interesting 
and provide a further comparison. 
A particular strength of this study was the fact that it was conducted outside of clinical 
trials. This reflects the efficacy of such treatments in patients in the setting of real clinical 
practice and highlights the importance of the analysis of expensive therapy in low and middle 
income countries.  
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6. CONCLUSION 
 31 
 
In conclusion, AA + P and ENZ represent an effective form of treatment for patients 
with mCRPC. Both drugs prolong survival, time to biochemical and radiological progression 
for patients at this stage of disease with acceptable toxicity profiles for both agents. 
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8. SUMMARY 
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Title: A RETROSPECTIVE STUDY COMPARING ABIRATERONE ACETATE AND 
ENZALUTAMIDE IN THE TREATMENT OF PATIENTS WITH METASTATIC 
CASTRATION-RESISTANT PROSTATE CANCER IN SPLIT 
Objectives: To retrospectively compare the efficacy of AA and ENZ in the treatment of 
patients with mCRPC in the post-docetaxel setting in terms of biochemical, radiological and 
clinical progression free survival (i.e. bPFS, rPFS and cPFS, respectively) and OS in 58 
consecutive patients in a single institution. We also evaluated the toxicity of both agents. 
 
Methods: A retrospective cohort study using the data collected from patients’ charts in the 
Department of Oncology and Radiotherapy in Split. A total of 58 consecutive mCRPC 
patients (n=58) treated with AA (1000 mg/day, 1h before or 2h after meal) plus P (2x5 mg) 
(n=27) and ENZ (160 mg per day) (n=31) from October 2015 until May 2018 in the post-
docetaxel setting were included in this study.   
Results: Despite the numerical difference in mOS, bPFS, rPFS, cPFS, in this relatively small 
number of patients, there was no statistically significant difference found between the two 
groups of patients.  
In comparison to the most significant randomised control trials for AA + P (COU-AA 301) 
and ENZ (AFFIRM), the results of our patients' treatment with these agents regarding mOS 
were even better. Namely, in the COU-AA 301 study, mOS was 14.8 months (40) while in 
our mCRPC patients treated with AA+P mOS was not reached. In the AFFIRM trial, mOS 
was 18.4 months (41) whereas in our mCRPC patients treated with ENZ mOS was 24 months. 
In other observed parameters such as bPFS or rPFS we achieved comparable results to the  
COU-AA 301 trial and the AFFIRM study (40,41). 
                                                                                                                                           
Regarding the observed toxicity in our patients, the incidence of certain side effects (among 
other typical side effects for each drug) did not differ significantly from those  observed in the  
randomized trials mentioned above.  
Conclusion: In conclusion, AA + P and ENZ represent an effective form of treatment  for 
patients with mCRPC. Both drugs prolong survival, time to biochemical and radiological 
progression for patients at this stage of disease with acceptable toxicity profiles for both 
agents. 
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9. CROATIAN SUMMARY/  SAŽETAK 
 40 
 
Naslov: RETROSPEKTIVNA STUDIJA USPOREDBE ABIRATERON ACETATA I 
ENZALUTAMIDA U LIJEČENJU BOLESNIKA S METASTATSKIM 
KASTRACIJSKI REZISTENTNIM RAKOM PROSTATE U SPLITU 
 
Ciljevi: Retrospektivno usporediti djelotvornost AA i ENZ u liječenju pacijenata s mCRPC 
nakon progresije pod docetakselom u smislu biokemijskog, radiološkog i kliničkog 
preţivljavanja bez progresije (tj. BPFS, rPFS i cPFS) i OS u 58 uzastopnih pacijenata u jednoj 
ustanovi. Također smo procijenili toksičnost oba lijeka. 
 
Metode: Retrospektivna kohortna studija pomoću podataka prikupljenih iz povijesti bolesti 
bolesnika u Klinici za onkologiju i radioterapiju u Splitu. Sveukupno 58 bolesnika s mCRPC 
(n = 58) koji su liječeni s AA (1000 mg / dan, 1h prije ili 2h nakon obroka) plus P (2x5 mg) (n 
= 27) i ENZ (160 mg dnevno) (n = 31) od listopada 2015. do svibnja 2018. nakon progresije 
pod docetakselom uključeni su u ovu studiju. 
 
Rezultati: Unatoč brojčanim razlikama u mOS, bPFS, rPFS, cPFS, s relativno malim brojem 
pacijenata, nije pronađena statistički značajna razlika između dviju skupina bolesnika. 
U usporedbi s najznačajnijim randomiziranim studijama za AA + P (COU-AA 301) i ENZ 
(AFFIRM), rezultati našeg liječenja bolesnika s navedenim lijekovima u medijanu OS bili su 
još bolji. Naime, u studiji COU-AA 301, mOS je iznosio 14,8 mjeseci (40) dok kod naših 
mCRPC bolesnika liječenih AA + P mOS nije postignut. U ispitivanju AFFIRM, mOS je 
iznosio 18,4 mjeseci (41), dok je kod naših mCRPC bolesnika liječenih ENZ mOS iznosio 24 
mjeseca. U drugim promatranim parametrima kao što su bPFS ili rPFS postigli smo 
usporedive rezultate s ispitivanjem COU-AA 301 i AFFIRM (40,41). 
 
Što se tiče promatrane toksičnosti kod naših bolesnika, učestalost određenih nuspojava (među 
ostalim tipičnim nuspojavama za svaki lijek) nije se značajno razlikovala od onih promatranih 
u gore spomenutim randomiziranim istraţivanjima. 
 
Zaključak: AA + P i ENZ predstavljaju učinkovit oblik liječenja bolesnika s mCRPC. Oba 
lijeka produljuju preţivljavanje, vrijeme do biokemijske i radiološke progresije pacijenata u 
ovoj fazi bolesti s prihvatljivim profilom toksičnosti za oba lijeka. 
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